IV Refractory testicular tumors 50-100 mg/m2 daily administered over 30-60 min on days 1-5 of each 21-day (or 28-day cycle), or 100 mg/m2 administered 30-60 min on days 1, 3, & 5 of each 21-day (or 28-day cycle). Small cell lung cancer Recommended dose: 35-50 mg/m2 daily administered over 30-60 min or longer for 4 consecutive days of each 21-day cycle. Usual dose: 50-120 mg/m2 daily for 5 days. Alternatively, 100 mg/m2 on alternate days to a total of 300 mg/m2. Courses may be repeated after 3-4 wk.
Not to be given via rapid IV inj. Not to be physically mixed w/ any other drug. Discontinue in severe hypersensitivity reaction. Severe myelosuppression w/ resulting infection or bleeding. Secondary leukemia w/ long term use. Withhold or reduce dose if platelet count <50,000/mm3 or ANC <500/mm3. Frequently observe for myelosuppression both during & after therapy. Monitor blood counts at the start of therapy & prior to each subsequent course of treatment. Renal impairment. Use effective contraception in females of reproductive potential during treatment & for at least 6 mth after final dose; in males w/ female sexual partners of reproductive potential during treatment & for 4 mth after final dose. Infertility in females & males. Pregnancy. Should not breastfeed during treatment. Paed patients. Premature infants (fatal gasping syndrome). Elderly.
L01CB01 - etoposide ; Belongs to the class of plant alkaloids and other natural products, podophyllotoxin derivatives. Used in the treatment of cancer.
Sign Out
